Antidiabetic medications prescribing pattern in patients with Myocardial infractio
Not Applicable
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Registration Number
- CTRI/2024/07/071065
- Lead Sponsor
- Justice K S Hegde Charitable Hospital Mangalore
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
T2DM patients of either gender aged 18 years and above with at least one cardiovascular coexisting condition
Exclusion Criteria
1. Patient with type 1 diabetes mellitus
2. Keto acidosis
3. Pregnant women.
4. Patients with CKD as comorbid condition
5. Patient with stroke psychiatric disorders, neurological disorders, nephrology, hepatology, oncological, respiratory disorders, infectious disorders
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Annual Rate of number of prescriptions of type of anti-diabetic medications in T2DM with Acute MI.Timepoint: At admission and discharge
- Secondary Outcome Measures
Name Time Method Demographic factors <br/ ><br>Other antidiabetic drug <br/ ><br>Co-morbidities <br/ ><br>Cardiovascular medications <br/ ><br>ASCVD (IHD, stroke), heart failure <br/ ><br>Residence type <br/ ><br>Habits <br/ ><br>Laboratory parameters <br/ ><br>Timepoint: At admission and discharge
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do SGLT2 inhibitors and GLP-1 agonists influence cardiovascular outcomes in Type 2 diabetes patients post-MI?
What is the comparative effectiveness of newer antidiabetic agents versus traditional therapies in reducing cardiac events in CTRI/2024/07/071065?
Which biomarkers, such as HbA1c or C-reactive protein, correlate with improved glycemic control and reduced MI recurrence in T2DM patients using antidiabetic drugs?
What adverse events are associated with antidiabetic medications in post-MI Type 2 diabetes patients, and how are they managed?
How do combination therapies involving metformin and SGLT2 inhibitors impact both diabetes management and cardiovascular risk in patients with acute MI?